Cargando…
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular mortality compared with non-diabetic individuals. There is a growing awareness that glycemic efficacy of anti-diabetic drugs does not necessarily translate to cardiovascular safety. Over the past few years, there...
Autores principales: | Xu, James, Rajaratnam, Rohan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288947/ https://www.ncbi.nlm.nih.gov/pubmed/28148253 http://dx.doi.org/10.1186/s12933-017-0499-5 |
Ejemplares similares
-
Preventive pharmacotherapy in type 2 diabetes mellitus
por: Choudhary, Neeraj, et al.
Publicado: (2012) -
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
por: Cheng, Vicky, et al.
Publicado: (2011) -
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
por: Koullias, Emmanouil S., et al.
Publicado: (2022) -
Pathophysiology, pharmacotherapy, cardiovascular disease
por: Sharma, Kamal H.
Publicado: (2015) -
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
por: Wu, Linda, et al.
Publicado: (2019)